AKEBIA THERAPEUTICS, INC.
245 First Street
Cambridge, Massachusetts 02142
October 29, 2018
VIA EDGAR
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Dorrie Yale, Erin Jaskot
Re: | Akebia Therapeutics, Inc. |
Registration Statement on Form S-4 (File No. 333-227622) Acceleration Request |
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, we hereby respectfully request acceleration of the effective date of the Registration Statement on Form S-4 (File No. 333-227622) (as amended, the Registration Statement) of Akebia Therapeutics, Inc. (the Company), so that such Registration Statement will be declared effective as of 4:00 p.m. Washington, D.C. time on October 30, 2018, or as soon thereafter as practicable.
Thank you for your assistance with this matter. If you have any questions regarding the foregoing, please do not hesitate to contact Daniel Rees of Latham & Watkins LLP at (714) 755-2244.
[Remainder of page intentionally left blank]
Very truly yours, | ||||
AKEBIA THERAPEUTICS, INC. | ||||
By: | /s/ Nicole R. Hadas | |||
Name: | Nicole R. Hadas | |||
Title: | Senior Vice President, General Counsel, and Secretary |
cc: Daniel Rees, Latham & Watkins LLP
[Signature page to S-4 Acceleration Request]